Health
Anyone on Ozempic or Wegovy told 'go to A&E' if they have 1 side effect
Key Points
Anyone on Ozempic or Wegovy told 'go to A&E' if they have 1 side effect A TikTok pharmacist has spoken out on a potentially serious but rare side effect of weight loss drugs Imagine waking up one morning and finding that your life has changed within the blink of an eye, and without any warning. A pharmacist has issued an urgent warning about a side effect affecting some people taking certain weight-loss and diabetes medicines and why they need to act quickly. Raj Patel, known as the Straight...
Anyone on Ozempic or Wegovy told 'go to A&E' if they have 1 side effect
A TikTok pharmacist has spoken out on a potentially serious but rare side effect of weight loss drugs
Imagine waking up one morning and finding that your life has changed within the blink of an eye, and without any warning. A pharmacist has issued an urgent warning about a side effect affecting some people taking certain weight-loss and diabetes medicines and why they need to act quickly.
Raj Patel, known as the Straight Talking Pharmacist on TikTok, shared the advice with his more than 100,000 followers in one of his recent videos. He described a rare condition affecting the blood supply to the optic nerve, which can cause sudden and potentially permanent sight loss.
In the clip, Mr Patel said: "No pain, but that still needs urgent checking. Not every vision change is caused by your medicine, but if you get sudden sight loss or quickly worsening eye symptoms, vision problems, you need to go to casualty or A&E." He explained that one possible cause is reduced blood flow to a nerve at the back of the eye.
The condition is called non-arteritic anterior ischaemic optic neuropathy (NAION), and the Medicines and Healthcare products Regulatory Agency (MHRA) says it has been very rarely reported in people taking semaglutide, a GLP-1 medication which is sold under the brand names Ozempic and Rybelsus, and prescribed for patients with type 2 diabetes. It is also sold as Wegovy, which is used for weight management and cardiovascular risk reduction in patients who are overweight or obese.
According to the MHRA, the condition typically causes sudden, painless loss of vision, usually in one eye. The MHRA updated its guidance in February, advising people taking semaglutide to attend eye casualty or A&E urgently if they experience sudden sight loss or rapidly worsening eyesight. It says the risk is very rare, estimated at up to one person in every 10,000 taking the medicine.
Ensure our latest Health headlines always appear at the top of your Google Search by making us a Preferred Source. Click here to activate or add us as Preferred Source in your Google search settings
Mr Patel also mentioned Mounjaro, but the MHRA's specific NAION warning concerns semaglutide rather than tirzepatide, the active ingredient in Mounjaro. The regulator says it is reviewing evidence for a possible association with other GLP-1 medicines, so the same confirmed warning should not be assumed to apply to every injection.
The NHS says sudden loss of vision in one or both eyes requires immediate action, advising people to go to A&E or call 999. It also warns people not to drive themselves and recommends taking any medicines they use with them.
Mr Patel's advice was clear: "Don't drive, don't stop the treatment yourself and tell the team what you take." The MHRA says semaglutide should be discontinued if NAION is confirmed, but patients should not make that decision themselves before medical assessment.
Any sudden loss of sight, including partial loss, should be treated as an emergency rather than something to monitor at home. People experiencing rapidly worsening vision while taking these medicines should seek urgent medical assessment and tell clinicians exactly what they have been prescribed.